

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary**

May 15, 2013

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Catherine Decker PharmD	Yes
3	Lawrence Fleming M.D.	No
4	Al Liegel, RPh	Yes
5	Kevin Izard M.D.	No
6	Steve Maike RPh	Yes
7	Pat Towers	Yes
8	Alicia Walker PharmD	Yes
9	Michael Witkovsky M.D.	No
10	James Boblin M.D.	Yes
11	Ward Brown, M.D.	Yes
12	Ronald Diamond, M.D.	No
13	William E. Raduege, M.D.	Yes

MAY 2013 THERAPEUTIC DRUG CLASS

ANGIOTENSIN MODULATORS
ANGIOTENSIN MODULATOR COMBINATIONS
BETA BLOCKERS
CALCIUM CHANNEL BLOCKERS
LIPOTROPICS, OTHER
LIPOTROPICS, STATINS
PAH AGENTS, ORAL AND INHALED
ANTICOAGULANTS
PLATELET AGGREGATION INHIBITORS
HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS
HYPOGLYCEMICS, MEGLITINIDES
HYPOGLYCEMICS, OTHER
HYPOGLYCEMICS, SULFONYLUREAS
HYPOGLYCEMICS, TZD
ANTIEMETIC/ANTIVERTIGO AGENTS
PANCREATIC ENZYMES
PROTON PUMP INHIBITORS
ULCERATIVE COLITIS AGENTS
H. PYLORI TREATMENT
ANTIBIOTICS, GI
ANTIBIOTICS, INHALED
ANTIBIOTICS, VAGINAL
ANTIFUNGALS, ORAL
ANTIVIRALS, ORAL
CEPHALOSPORINS AND RELATED AGENTS
FLOROQUINOLONES, ORAL
MACROLIDES/KETOLIDES
TETRACYCLINES
ACNE AGENTS, TOPICAL
ANTIBIOTICS, TOPICAL
ANTIFUNGALS, TOPICAL
ANTIPARASITICS, TOPICAL
ANTIVIRALS, TOPICAL

ANALGESICS, MISCELLANEOUS
ANALGESICS, NARCOTICS LONG
ANALGESICS, NARCOTICS SHORT
OPIATE DEPENDENCY
ANTIMIGRAINE AGENTS
SKELETAL MUSCLE RELAXANTS
BLADDER RELAXANT PREPARATIONS
BONE RESORPTION SUPPRESSION AND RELATED AGENTS
ERYTHROPOIESIS STIMULATING PROTEINS
GROWTH HORMONE
ANDROGENIC AGENTS
BPH TREATMENTS
PHOSPHATE BINDERS
HEPATITIS B AGENTS
HEPATITIS C AGENTS
HIV/AIDS
MULTIPLE SCLEROSIS AGENTS
IRRITABLE BOWEL SYNDROME-**NEW CLASS**
H2 ANTAGONISTS-**NEW CLASS**

ANGIEOTENSIN MODULATORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LISINOPRIL HCTZ (ORAL)	10.9%	ON	Yes-Generic			
ENALAPRIL HCTZ (ORAL)	0.4%	ON	Yes-Generic			
MOEXIPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
BENAZEPRIL HCTZ (ORAL)	0.7%	ON	Yes-Generic			
QUINAPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
CAPTOPRIL HCTZ (ORAL)	0.0%	ON	Yes-Generic			
FOSINOPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
CAPTOPRIL (ORAL)	0.7%	ON	Yes-Generic			
LISINOPRIL (ORAL)	45.1%	ON	Yes-Generic			
ENALAPRIL (ORAL)	6.2%	ON	Yes-Generic			
RAMIPRIL (ORAL)	0.5%	ON	Yes-Generic			
BENAZEPRIL (ORAL)	3.5%	ON	Yes-Generic			
MOEXIPRIL (ORAL)	0.0%	OFF	No-Generic			
FOSINOPRIL (ORAL)	0.0%	OFF	No-Generic			
QUINAPRIL (ORAL)	0.5%	ON	No-Generic			
TRANDOLAPRIL (ORAL)	0.0%	OFF	No-Generic			
PERINDOPRIL (ORAL)	0.0%	OFF	No-Generic			
MICARDIS (ORAL)	0.1%	OFF	No			
BENICAR (ORAL)	0.4%	OFF	No			
AVAPRO (ORAL)	0.0%	OFF	No			
DIOVAN (ORAL)	4.7%	ON	Yes			
LOSARTAN (ORAL)	17.7%	ON	Yes-Generic			
IRBESARTAN (ORAL)	0.2%	OFF	No-Generic			
ATACAND (ORAL)	0.1%	OFF	No			
TEVETEN (ORAL)	0.0%	OFF	No			
EDARBI (ORAL)	0.0%	OFF	No			
EPROSARTAN (ORAL)	0.0%	OFF	No-Generic			
MICARDIS HCT (ORAL)	0.1%	OFF	No			
ATACAND HCT (ORAL)	0.0%	OFF	No			
BENICAR HCT (ORAL)	0.2%	OFF	No			
DIOVAN HCT (ORAL)	1.5%	ON	Yes			

LOSARTAN HCTZ (ORAL)	5.7%	ON	Yes-Generic			
IRBESARTAN HCTZ (ORAL)	0.0%	NR	No-Generic			
TEVETEN HCT (ORAL)	0.0%	OFF	No			
EDARBYCLOR (ORAL)	0.0%	OFF	No			
AVALIDE (ORAL)	0.0%	OFF	No			
VALSARTAN HCTZ (ORAL)	0.5%	NR	No-Generic			
CANDESARTAN HCTZ (ORAL)	0.0%	NR	No-Generic			
TEKURNA HCT (ORAL)	0.0%	OFF	No			
TEKURNA (ORAL)	0.2%	OFF	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - All members were in favor of the motion
 - Motion passes

ANGIOTENSIN MODULATOR COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LOTREL (ORAL)	4.8%	ON	Yes			
TARKA (ORAL)	1.4%	ON	Yes			
EXFORGE (ORAL)	30.9%	ON	Yes			
EXFORGE HCT (ORAL)	8.9%	ON	Yes			
AZOR (ORAL)	36.8%	ON	Yes			
AMTURNIDE (ORAL)	0.0%	OFF	No			
TRIBENZOR (ORAL)	13.8%	ON	Yes			
TEKAMLO (ORAL)	0.0%	OFF	No			
TWYNSTA (ORAL)	0.1%	OFF	No			
AMLODIPINE / BENAZEPRIL (ORAL)	3.1%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of the motion
 - Motion passes

BETA BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ATENOLOL (ORAL)	20.8%	ON	Yes-Generic			
TOPROL XL (ORAL)	5.3%	ON	Yes			
METOPROLOL (ORAL)	28.9%	ON	Yes-Generic			
BISOPROLOL HCTZ (ORAL)	0.1%	OFF	No-Generic			
CARVEDILOL (ORAL)	11.3%	ON	Yes-Generic			
PROPRANOLOL SOLUTION (ORAL)	0.4%	ON	Yes-Generic			
PROPRANOLOL TABLET (ORAL)	5.5%	ON	Yes-Generic			
ATENOLOL / CHLORTHALIDONE (ORAL)	1.2%	ON	Yes-Generic			
DUTOPROL (ORAL)	0.0%	OFF	No			
NADOLOL / BENDROFLUMETHIAZIDE (ORAL)	0.0%	OFF	No-Generic			
LEVATOL (ORAL)	0.0%	OFF	No			
SOTALOL (ORAL)	0.7%	ON	Yes-Generic			
ACEBUTOLOL (ORAL)	0.1%	ON	Yes-Generic			
BISOPROLOL (ORAL)	0.2%	OFF	No-Generic			
BYSTOLIC (ORAL)	1.8%	OFF	No			
PROPRANOLOL ER (ORAL)	3.1%	ON	Yes-Generic			
LABELALOL (ORAL)	2.9%	ON	No-Generic			
INNOPRAN XL (ORAL)	0.0%	OFF	No			
PINDOLOL (ORAL)	0.1%	OFF	No-Generic			
NADOLOL (ORAL)	1.1%	ON	No-Generic			
METOPROLOL XL (ORAL)	16.5%	ON	No-Generic			
METOPROLOL / HCTZ (ORAL)	0.0%	OFF	No-Generic			
TIMOLOL (ORAL)	0.0%	OFF	No-Generic			
COREG CR (ORAL)	0.1%	OFF	No			
PROPRANOLOL / HCTZ (ORAL)	0.0%	ON	No-Generic			
BETAXOLOL (ORAL)	0.0%	OFF	No-Generic			

- Discussion:
The committee had discussion regarding the pregnancy category for labetalol.
Provider Synergies noted that there are other preferred products that are pregnancy Category C. Rachel Currans-Henry explained Toprol XL shortage in past months, and manufacturer has confirmed stock is now available.

Motion 1:

- Alicia Walker made a motion to accept staff recommendations but to have labetalol remain preferred.
 - Second- Steve Maike
 - The vote was 4 to 5 in favor of the motion. James Boblin, Ward Brown, Pat Towers, Alicia Walker, and William Raduege were opposed to the motion.
 - Motion failed.

Motion 2:

- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- James Boblin
 - The vote was 5 to 4 in favor of the motion. Rosanne Barber, Alicia Walker, Catherine Decker and Steve Maike were opposed to the motion.
 - Motion passes.

CALCIUM CHANNEL BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMLODIPINE (ORAL)	68.3%	ON	Yes-Generic			
CARDIZEM LA (ORAL)	0.1%	OFF	Yes			
DILTIAZEM TABLET (ORAL)	1.5%	ON	Yes-Generic			
VERAPAMIL TABLET (ORAL)	1.1%	ON	Yes-Generic			
VERAPAMIL TABLET ER (ORAL)	4.3%	ON	Yes-Generic			
VERAPAMIL CAPSULE (ORAL)	1.3%	ON	Yes-Generic			
ISRADIPINE (ORAL)	0.2%	OFF	No-Generic			
CARDENE SR (ORAL)	0.0%	OFF	No			
NIFEDIPINE ER (ORAL)	6.1%	ON	Yes-Generic			
DILTIAZEM CAPSULE ER (ORAL)	16.2%	ON	Yes-Generic			
VERAPAMIL 360 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
FELODIPINE ER (ORAL)	0.2%	OFF	No-Generic			
NIFEDIPINE IR (ORAL)	0.4%	ON	Yes-Generic			
MATZIM LA (ORAL)	0.0%	OFF	No-Generic			
NICARDIPINE (ORAL)	0.0%	ON	No-Generic			
NISOLDIPINE (ORAL)	0.1%	OFF	No-Generic			
VERAPAMIL ER PM (ORAL)	0.0%	OFF	No-Generic			
NIMODIPINE (ORAL)	0.0%	ON	Yes-Generic			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

LIPOTROPICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ANTARA (ORAL)	0.0%	OFF	No			
TRICOR (ORAL)	21.2%	ON	Yes-Generic			
NIACOR (ORAL)	0.0%	ON	Yes			
TRIGLIDE (ORAL)	0.0%	OFF	No			
TRILIPIX (ORAL)	6.3%	ON	Yes			
FENOFIBRIC ACID (ORAL)	0.0%	ON	Yes-Generic			
GEMFIBROZIL (ORAL)	13.3%	ON	Yes-Generic			
CHOLESTYRAMINE/ASPARTAME (ORAL)	2.1%	ON	Yes-Generic			
NIASPAN (ORAL)	20.1%	ON	Yes			
COLESTIPOL TABLET (ORAL)	0.5%	OFF	No-Generic			
CHOLESTYRAMINE/SUCROSE (ORAL)	3.5%	ON	Yes-Generic			
ZETIA (ORAL)	12.7%	OFF	No			
FENOFIBRATE TABLET (LOFIBRA) (ORAL)	9.9%	ON	Yes-Generic			
LIPOFEN (ORAL)	0.0%	OFF	No			
FENOFIBRATE TABLET (AG) (TRICOR) (ORAL)	6.8%	NR	No-Generic			
FENOFIBRATE CAPSULE (LOFIBRA)(ORAL)	0.6%	OFF	No-Generic			
WELCHOL TABLET (ORAL)	1.2%	OFF	No			
FIBRICOR (ORAL)	0.0%	OFF	No			
WELCHOL POWDER PACK (ORAL)	0.2%	OFF	No			
FENOFIBRATE (ANTARA) (ORAL)	0.0%	NR	No-Generic			
LOVAZA (ORAL)	1.1%	OFF	Yes			
FENOFIBRATE TABLET (TRICOR) (ORAL)	0.4%	NR	No-Generic			
VASCEPA (ORAL)	0.0%	NR	No			
COLESTIPOL GRANULES (ORAL)	0.0%	OFF	No-Generic			

- Discussion:
 - Rachel Currans-Henry explained to the committee that we continue require clinical PA on Lovaza.
- Catherine Dec ker made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion
 - Motion passes

LIPOTROPICS, STATINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SIMVASTATIN (ORAL)	36.8%	ON	Yes-Generic			
LESCOL XL (ORAL)	0.5%	ON	Yes			
LESCOL (ORAL)	0.5%	ON	Yes			
ALTOPREV (ORAL)	0.0%	OFF	No			
PRAVASTATIN (ORAL)	11.8%	ON	Yes-Generic			
LOVASTATIN (ORAL)	7.0%	ON	Yes-Generic			
ATORVASTATIN (ORAL)	38.1%	ON	Yes-Generic			
CRESTOR (ORAL)	4.7%	OFF	No			
ADVICOR (ORAL)	0.0%	OFF	No			
SIMCOR (ORAL)	0.1%	ON	Yes			
VYTORIN (ORAL)	0.2%	OFF	No			
LIVALO (ORAL)	0.1%	OFF	No			
FLUVASTATIN (ORAL)	0.0%	OFF	No-Generic			
AMLODIPINE-ATORVASTATIN (ORAL)	0.0%	OFF	No-Generic			
LIPITOR (ORAL)	0.2%	OFF	No			
CADUET (ORAL)	0.0%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

PAH AGENTS, ORAL AND INHALED

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VENTAVIS (INHALATION)	2.8%	OFF	No			
TYVASO (INHALATION)	1.4%	OFF	No			
SILDENAFIL (ORAL)	17.1%	OFF	Yes-Generic			
ADCIRCA (ORAL)	31.3%	ON	No			
TRACLEER (ORAL)	31.3%	ON	Yes			
LETAIRIS (ORAL)	16.1%	ON	Yes			

- Discussion:
Steve Maike questioned if there would be grandfathering on Adcirca. Staff confirmed members currently taking Adcirca will be grandfathered.
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

ANTICOAGULANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WARFARIN (ORAL)	88.7%	ON	Yes-Generic			
PRADAXA (ORAL)	1.6%	OFF	Yes			
XARELTO (ORAL)	1.4%	ON	Yes			
ELIQUIS (ORAL)	0.0%	NR	No			
ENOXAPARIN SODIUM VIAL (AG)(SUBCUTANEOUS)	0.0%	OFF	No-Generic			
LOVENOX VIAL (SUBCUTANE.)	0.2%	ON	Yes			
ENOXAPARIN SODIUM VIAL (SUBCUTANEOUS)	0.0%	OFF	No-Generic			
FRAGMIN VIAL (SUBCUTANE.)	0.0%	OFF	No			
FRAGMIN DISP SYRIN (SUBCUTANE.)	0.6%	ON	Yes			
LOVENOX SYRINGE (SUBCUTANE.)	6.9%	ON	Yes			
ENOXAPARIN SYRINGE (SUBCUTANE.)	0.4%	OFF	No-Generic			
ENOXAPARIN SYRINGE (AUTH GEN) (SUBCUTANE.)	0.1%	OFF	No-Generic			
ARIXTRA (SUBCUTANE.)	0.0%	OFF	No			
FONDAPARINUX (SUBCUTANE.)	0.1%	OFF	No-Generic			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

PLATELET AGGREGATION INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOPIDOGREL (ORAL)	93.1%	NR	Yes-Generic			
TICLOPIDINE (ORAL)	0.2%	OFF	No-Generic			
AGGRENEX (ORAL)	5.2%	ON	Yes			
DIPYRIDAMOLE (ORAL)	0.3%	ON	Yes-Generic			
BRILINTA (ORAL)	0.1%	OFF	No			
EFFIENT (ORAL)	1.0%	OFF	No			

- Discussion:
- Rachel Currans-Henry noted that the release of generic clopidogrel resulted in significant savings for this class.
- Ward Brown made a motion to accept staff recommendations presented.
 - Second- Pat Towers
 - All members were in favor of this motion
 - Motion passes

HYPOGLYCEMICS, ALPHA-GLUCOSIDEASE INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GLYSET(ORAL)	10.4%	ON	Yes			
ACARBOSE(ORAL)	89.6%	ON	Yes-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes.

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SYMLIN (SUBCUTANE.)	0.0%	OFF	No			
SYMLIN PENS (SUBCUTANE.)	0.3%	OFF	No			
JANUMET XR (ORAL)	0.1%	NR	Yes			
JENTADUETO (ORAL)	0.4%	ON	Yes			
JANUMET (ORAL)	14.3%	ON	Yes			
JUVISYNC (ORAL)	0.0%	OFF	Yes			
JANUVIA (ORAL)	63.9%	ON	Yes			
TRADJENTA (ORAL)	2.7%	ON	Yes			
KOMBIGLYZE XR (ORAL)	3.3%	ON	No			
ONGLYZA (ORAL)	11.0%	ON	No			
NESINA (ORAL)	0.0%	NR	No			
OSENI (ORAL)	0.0%	NR	No			
KAZANO (ORAL)	0.0%	NR	No			
BYETTA PENS (SUBCUTANE.)	3.2%	ON	Yes			
VICTOZA (SUBCUTANE.)	0.8%	OFF	No			
BYDUREON (SUBCUTANE.)	0.0%	OFF	No			

- Discussion:
Rachel Currans-Henry explained all injectables will continue to require PA.
- Al Liegel made a motion to accept staff recommendations as presented
 - Second-Steve Maike
 - All members were in favor of this motion.
 - Motion passes

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HUMULIN 70/30 OTC (SUBCUTANE.)	3.6%	ON	Yes			
HUMALOG MIX VIAL (SUBCUTANE.)	1.4%	ON	Yes			
HUMULIN OTC (SUBCUTANE.)	6.0%	ON	Yes			
HUMALOG (SUBCUTANE.)	13.5%	ON	Yes			
LEVEMIR VIAL (SUBCUTANE)	0.3%	OFF	Yes			
NOVOLOG MIX PEN (SUBCUTANE)	0.1%	OFF	No			
NOVOLOG VIAL (SUBCUTANE)	0.3%	OFF	No			
NOVOLOG CARTRIDGE (SUBCUTANE)	0.1%	OFF	No			
NOVOLOG PEN (SUBCUTANE)	0.3%	OFF	No			
LANTUS VIAL (SUBCUTANE)	18.0%	ON	Yes			
LEVEMIR PENS (SUBCUTANE.)	0.7%	OFF	Yes			
HUMALOG MIX PEN (SUBCUTANE.)	2.7%	ON	Yes			
APIDRA VIAL (SUBCUTANE.)	0.1%	OFF	No			
HUMALOG PEN (SUBCUTANE.)	18.0%	ON	Yes			
HUMALOG CARTRIDGE (SUBCUTANE.)	1.9%	ON	Yes			
NOVOLOG MIX VIAL (SUBCUTANE.)	0.0%	OFF	No			
LANTUS CARTRIDGE (SUBCUTANE.)	0.0%	ON	Yes			
NOVOLIN 70/30 VIAL OTC (SUBCUTANE.)	0.7%	OFF	No			
HUMULIN 500 U/M VIAL (SUBCUTANE.)	0.6%	ON	Yes			
APIDRA SOLOSTAR PEN (SUB-Q)	0.0%	OFF	No			
LANTUS SOLOSTAR PEN	28.8%	ON	Yes			

(SUBCUTANE.)						
HUMULIN PEN OTC (SUBCUTANE.)	1.2%	ON	Yes			
HUMULIN 70/30 PEN OTC (SUBCUTANE)	1.6%	ON	Yes			

- Discussion:
 - Rachel Currans-Henry explained to the committee that Levemir is pregnancy category B.
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of this motion.
 - Motion passes

HYPOGLYCEMICS, MEGLITINIDES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PRANDIN (ORAL)	83.1%	ON	Yes			
NATEGLINIDE (ORAL)	16.9%	OFF	No-Generic			
PRANDIMET (ORAL)	0.0%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

HYPOGLYCEMICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METFORMIN (ORAL)	78.3%	ON	Yes-Generic			
METFORMIN ER (ORAL)	21.6%	ON	Yes-Generic			
RIOMET (ORAL)	0.1%	ON	Yes			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion.
 - Motion passes

HYPOGLYCEMICS, SULFONYLUREAS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GLIPIZIDE (ORAL)	26.3%	ON	Yes-Generic			
GLIMEPIRIDE (ORAL)	24.0%	ON	Yes-Generic			
GLYBURIDE MICRONIZED (ORAL)	1.0%	ON	Yes-Generic			
GLYBURIDE-METFORMIN (ORAL)	5.3%	ON	Yes-Generic			
GLYBURIDE (ORAL)	20.8%	ON	Yes-Generic			
GLIPIZIDE ER (ORAL)	21.6%	ON	Yes-Generic			
CHLORPROPAMIDE (ORAL)	0.0%	ON	Yes-Generic			
GLIPIZIDE-METFORMIN (ORAL)	0.8%	ON	Yes-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

HYPOGLYCEMICS, TZD						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PIOGLITAZONE (ORAL)	1.9%	ON	Yes-Generic			
DUETACT (ORAL)	0.0%	ON	No			
PIOGLITAZONE / METFORMIN (ORAL)	0.1%	OFF	No-Generic			
AVANDAMET (ORAL)	0.0%	OFF	No			
AVANDIA (ORAL)	0.0%	OFF	No			
ACTOPLUS MET XR (ORAL)	0.2%	OFF	No			
AVANDARYL (ORAL)	0.0%	OFF	No			

PIOGLITAZONE/GLIMEPIRIDE (ORAL)	0.0%	OFF	No-Generic			
ACTOPLUS MET (ORAL)	2.4%	ON	No			

- Discussion:
Lynn Radmer indicated that the committees cost sheets did not accurately reflect the current utilization for Actos, due to recent Actos switch to BMN policy.
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion.
 - Motion passes

ANTIEMETIC/ANTIVERTIGO AGENTS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MECLIZINE OTC (ORAL)	1.7%	ON	Yes-Generic			
METOCLOPRAMIDE TABLET (ORAL)	11.3%	ON	Yes-Generic			
PROCHLORPERAZINE (ORAL)	6.2%	ON	Yes-Generic			
MECLIZINE (ORAL)	7.9%	ON	Yes-Generic			
PROMETHAZINE SYRUP (ORAL)	1.4%	ON	Yes-Generic			
PROMETHAZINE TABLET (ORAL)	6.5%	ON	Yes-Generic			
METOCLOPRAMIDE SOLUTION (ORAL)	0.7%	ON	Yes-Generic			
ONDANSETRON TABLETS (ORAL)	24.1%	ON	Yes-Generic			
ONDANSETRON ODT (ORAL)	35.3%	ON	Yes-Generic			
GRANISOL SOLUTION (ORAL)	0.0%	OFF	No			
TRANSDERM-SCOP (TRANSDERM)	2.2%	ON	Yes			
PROMETHAZINE (RECTAL)	0.8%	ON	Yes-Generic			
PROCHLORPERAZINE (RECTAL)	0.3%	ON	Yes-Generic			
TRIMETHOBENZAMIDE (ORAL)	0.0%	ON	Yes-Generic			
MARINOL (ORAL)	0.3%	ON	Yes			
ONDANSETRON SOLUTION (ORAL)	0.8%	ON	Yes-Generic			
METOZOLV ODT (ORAL)	0.0%	OFF	No			
EMEND (ORAL)	0.1%	ON	Yes			
EMEND PACK (ORAL)	0.1%	ON	Yes			
PROMETHAZINE 50 MG (RECTAL)	0.0%	ON	Yes-Generic			
DRONABINAL (ORAL)	0.1%	OFF	No-Generic			
GRANISETRON (ORAL)	0.0%	OFF	No-Generic			
ANZEMET (ORAL)	0.0%	OFF	No			
SANCUSO (TRANSDERMAL)	0.0%	OFF	No			
CESAMET (ORAL)	0.0%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of this motion
 - Motion passes

PANCREATIC ENZYMES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANCRELIPASE (ORAL)	15.4%	ON	Yes			
ZENPEP (ORAL)	37.3%	ON	Yes			
CREON (ORAL)	39.7%	OFF	No			
PANCREAZE (ORAL)	7.1%	OFF	No			
PERTZYE (ORAL)	0.2%	NR	No			
ULTRESA (ORAL)	0.0%	NR	No			
VIOKACE (ORAL)	0.3%	NR	No			

- Discussion:
Rachel Currans-Henry indicated that Creon market share moved from 49% to 39% since last year. Staff confirmed that members previously grandfathered for Creon will remain grandfathered until a generic becomes available.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - All members were in favor of this motion
 - Motion passes

PROTON PUMP INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PROTONIX SUSPENSION (ORAL)	0.1%	ON	Yes			
PANTOPRAZOLE (ORAL)	11.9%	ON	Yes-Generic			
ACIPHEX (ORAL)	10.8%	ON	Yes			
NEXIUM (ORAL)	2.3%	OFF	No			
OMEPRAZOLE (ORAL)	71.8%	ON	Yes-Generic			
NEXIUM SUSPENSION (ORAL)	0.0%	OFF	Yes			
DEXILANT (ORAL)	0.5%	OFF	No			
LANSOPRAZOLE CAPSULES (ORAL)	1.5%	OFF	No-Generic			
LANSOPRAZOLE SOLUTAB (ORAL)	0.0%	OFF	No-Generic			
PREVACID SOLUTAB (ORAL)	0.0%	OFF	No			
PRILOSEC SUSPENSION (ORAL)	0.0%	ON	Yes			
OMEPRAZOLE/SODIUM BICARBONATE (ORAL)	0.0%	OFF	No-Generic			

- Discussion:
Rachel Currans-Henry and Rick Pope explained to the committee that Nexium is going generic May 2014, something the committee may be able to consider for the next review of this class. Rick Pope indicated there is no generic exclusivity period.

- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

ULCERATIVE COLITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DIPENTUM (ORAL)	0.1%	OFF	No			
SULFASALAZINE DR(ORAL)	6.3%	ON	Yes-Generic			
SULFASALAZINE (ORAL)	21.7%	ON	Yes-Generic			
BALSALAZIDE (ORAL)	6.1%	ON	Yes-Generic			
ASACOL (ORAL)	44.8%	ON	Yes			
APRISO (ORAL)	7.5%	ON	Yes			
LIALDA (ORAL)	3.0%	ON	Yes			
PENTASA (ORAL)	6.1%	OFF	No			
ASACOL HD (ORAL)	0.8%	OFF	No			
GIAZO (ORAL)	0.0%	NR	No			
ROWASA (RECTAL)	0.0%	OFF	Yes			
CANASA (RECTAL)	3.0%	ON	Yes			
MESALAMINE (RECTAL)	0.3%	OFF	No-Generic			
MESALAMINE KIT (RECTAL)	0.2%	OFF	No-Generic			
SFROWASA (RECTAL)	0.0%	OFF	No			

- Discussion:
Rick Pope indicated that Asacol is no longer manufactured.
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Alicia Walker
 - All members were in favor of this motion
 - Motion passes

H. PYLORI TREATMENT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HELIDAC (ORAL)	85.0%	ON	Yes			
PREVPAC (ORAL)	8.5%	OFF	Yes			
PYLERA (ORAL)	6.5%	ON	No			
OMECLAMOX-PAK (ORAL)	0.0%	NR	No			

- Discussion:
Rachel Currans-Henry commented that Prevpac is being added due to lower cost and product contains different type of antibiotic than Helidac.

- William Raduege made a motion to accept staff recommendations as presented
 - Second- Catherine Decker
 - The vote was 8 to 1 in favor of the motion. Alicia Walker opposed.
 - Motion passes

ANTIBIOTICS, GI						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METRONIDAZOLE TABLET (ORAL)	96.2%	ON	Yes-Generic			
TINDAMAX (ORAL)	0.0%	OFF	No			
NEOMYCIN (ORAL)	0.4%	ON	Yes-Generic			
VANCOICIN HCL (ORAL)	1.0%	ON	Yes			
FLAGYL ER (ORAL)	0.0%	OFF	No			
ALINIA SUSPENSION (ORAL)	0.1%	ON	YES			
TINIDAZOLE (ORAL)	0.2%	OFF	No-Generic			
ALINIA TABLET (ORAL)	0.0%	ON	YES			
XIFAXAN (ORAL)	1.6%	OFF	No			
VANCOMYCIN HCL (ORAL)	0.1%	OFF	No-Generic			
DIFICID TABLET (ORAL)	0.1%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

ANTIBIOTICS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOBI (INHALATION)	92.8%	ON	Yes			
CAYSTON (INHALATION)	7.2%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - All members were in favor of this motion.
 - Motion passes

ANTIBIOTICS, VAGINAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VANDAZOLE(VAGINAL)	5.0%	ON	Yes			
METRONIDAZOLE (VAGINAL)	83.2%	ON	Yes-Generic			
CLEOCIN OVULES(VAGINAL)	3.1%	ON	Yes			
CLINDAMYCIN(VAGINAL)	8.7%	ON	Yes-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion.
 - Motion passes

ANTIFUNGALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUCONAZOLE TABLET (ORAL)	68.0%	ON	Yes-Generic			
KETOCONAZOLE (ORAL)	1.2%	ON	Yes-Generic			
TERBINAFINE (ORAL)	4.7%	ON	Yes-Generic			
NYSTATIN SUSPENSION (ORAL)	17.3%	ON	Yes-Generic			
CLOTRIMAZOLE (MUCOUS MEM)	0.1%	OFF	No-Generic			
GRIS-PEG (ORAL)	0.6%	ON	Yes			
FLUCONAZOLE SUSPENSION (ORAL)	3.0%	ON	Yes-Generic			
NYSTATIN TABLET (ORAL)	0.2%	ON	Yes-Generic			
GRISEOFULVIN SUSPENSION (ORAL)	3.8%	ON	Yes-Generic			
GRISEOFULVIN TABLETS (ORAL)	0.0%	OFF	No-Generic			
GRISEOFULVIN ULTRAMICROSIZE (ORAL)	0.0%	OFF	No-Generic			
LAMISIL GRANULES (ORAL)	0.0%	OFF	No			
NYSTATIN POWDER (ORAL)	0.3%	ON	Yes-Generic			
GRIFULVIN V TABLETS (ORAL)	0.0%	OFF	No			
SPORANOX SOLUTION (ORAL)	0.0%	OFF	No			
ITRACONAZOLE (ORAL)	0.3%	ON	Yes-Generic			
ONMEL (ORAL)	0.0%	NR	No			
VFEND SUSPENSION (ORAL)	0.0%	OFF	No			
NOXAFIL (ORAL)	0.1%	OFF	No			
VORICONAZOLE TABLETS (ORAL)	0.2%	OFF	No-Generic			
VFEND TABLET (ORAL)	0.0%	OFF	No			
FLUCYTOSINE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of the motion
 - Motion passes

ANTIVIRALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACYCLOVIR CAPSULE (ORAL)	3.0%	ON	Yes-Generic			
AMANTADINE SYRUP (ORAL)	0.2%	ON	Yes-Generic			
ACYCLOVIR TABLET (ORAL)	17.9%	ON	Yes-Generic			
RIMANTADINE (ORAL)	0.0%	ON	Yes-Generic			
RELENZA (INHALATION)	0.0%	ON	Yes			
AMANTADINE TABLET (ORAL)	0.9%	ON	Yes-Generic			
TAMIFLU CAPSULE (ORAL)	15.0%	ON	Yes			
ACYCLOVIR SUSPENSION (ORAL)	1.9%	ON	Yes-Generic			
VALACYCLOVIR (ORAL)	50.9%	ON	Yes-Generic			
AMANTADINE CAPSULE (ORAL)	2.4%	ON	No-Generic			
FAMCICLOVIR (ORAL)	0.1%	OFF	No-Generic			
TAMIFLU SUSPENSION (ORAL)	7.6%	ON	Yes			

- Discussion: None
- Steve Maiké made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

CEPHALOSPORINS AND RELATED ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AUGMENTIN 125 SUSPENSION (ORAL)	0.0%	ON	Yes			
CEPHALEXIN CAPSULE (ORAL)	21.6%	ON	Yes-Generic			
CEFADROXIL CAPSULE (ORAL)	1.5%	ON	Yes-Generic			
CEFUROXIME TABLET (ORAL)	4.1%	ON	Yes-Generic			
CEPHALEXIN SUSPENSION (ORAL)	5.4%	ON	Yes-Generic			
SUPRAX TABLET (ORAL)	0.6%	ON	Yes			
AMOXICILLIN/CLAV TABLET (ORAL)	25.4%	ON	Yes-Generic			
CEPHALEXIN TABLET (ORAL)	0.0%	ON	Yes-Generic			

AMOXICILLIN/CLAV SUSPENSION (ORAL)	17.5%	ON	Yes-Generic			
SUPRAX SUSPENSION (ORAL)	0.3%	ON	Yes			
AMOXICILLIN/CLAV CHEW TABLET (ORAL)	0.4%	ON	Yes-Generic			
CEFPROZIL TABLET (ORAL)	0.9%	ON	Yes-Generic			
CEFACTOR CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
CEFACTOR TABLET ER (ORAL)	0.0%	OFF	No-Generic			
CEFPROZIL SUSPENSION (ORAL)	2.2%	ON	Yes-Generic			
CEFADROXIL SUSPENSION (ORAL)	0.4%	ON	Yes-Generic			
CEDAX CAPSULE (ORAL)	0.0%	OFF	No			
CEFDINIR SUSPENSION (ORAL)	14.9%	ON	Yes-Generic			
CEFDINIR CAPSULE (ORAL)	4.3%	ON	Yes-Generic			
CEFADROXIL TABLET (ORAL)	0.0%	ON	Yes-Generic			
SUPRAX TAB CHEW (ORAL)	0.0%	NR	No			
CEFTIN SUSPENSION (ORAL)	0.4%	ON	Yes			
CEFPODOXIME SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
AMOXICILLIN/CLAV XR (ORAL)	0.0%	OFF	No-Generic			
CEFPODOXIME TABLET (ORAL)	0.0%	OFF	No-Generic			
AUGMENTIN 250 SUSPENSION (ORAL)	0.0%	ON	Yes			
CEFACTOR SUSPENSION (ORAL)	0.0%	ON	Yes-Generic			
CEDAX SUSPENSION (ORAL)	0.0%	ON	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

PENICILLINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMOXICILLIN TABLET (ORAL)	9.2%	ON	Yes-Generic			
AMOXICILLIN CAPSULE (ORAL)	25.7%	ON	Yes-Generic			

AMPICILLIN CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
PENICILLIN V POTASSIUM SUSPENSION (ORAL)	1.6%	ON	Yes-Generic			
AMOXICILLIN SUSPENSION (ORAL)	50.9%	ON	Yes-Generic			
PENICILLIN V POTASSIUM TABLET (ORAL)	9.8%	ON	Yes-Generic			
AMOXICILLIN TAB CHEW (ORAL)	1.9%	ON	Yes-Generic			
DICLOXACILLIN (ORAL)	0.8%	ON	Yes-Generic			
AMPICILLIN SUSPENSION (ORAL)	0.0%	ON	Yes-Generic			

- Discussion: None
- Willilam Raduege made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion.
 - Motion passes

FLUOROQUINOLONES, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CIPROFLOXACIN TABLET (ORAL)	65.7%	ON	Yes-Generic			
LEVOFLOXACIN TABLET (ORAL)	33.7%	ON	Yes-Generic			
AVELOX (ORAL)	0.2%	OFF	No			
NOROXIN (ORAL)	0.0%	OFF	No			
CIPROFLOXACIN ER (ORAL)	0.0%	OFF	No-Generic			
OFLOXACIN (ORAL)	0.0%	OFF	No-Generic			
LEVAQUIN SOLUTION (ORAL)	0.0%	OFF	No			
CIPRO SUSPENSION (ORAL)	0.2%	OFF	No			
LEVOFLOXACIN SOLUTION (ORAL)	0.1%	OFF	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of this motion.
 - Motion passes

MACROLIDES/KETOLIDESS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZITHROMYCIN TABLET (ORAL)	60.8%	ON	Yes-Generic			
AZITHROMYCIN PACKET (ORAL)	0.2%	ON	Yes-Generic			
AZITHROMYCIN SUSPENSION (ORAL)	35.3%	ON	Yes-Generic			
ZMAX (ORAL)	0.0%	OFF	No			
KETEK (ORAL)	0.0%	OFF	No			
PCE (ORAL)	0.0%	ON	Yes			
ERY-TAB (ORAL)	0.4%	ON	Yes			
E.E.S. 400 TABLET (ORAL)	0.1%	ON	Yes-Generic			
CLARITHROMYCIN SUSPENSION (ORAL)	0.4%	ON	Yes-Generic			
CLARITHROMYCIN TABLET (ORAL)	2.0%	ON	Yes-Generic			
ERYTHROCIN (ORAL)	0.1%	ON	Yes			
ERYTHROMYCIN BASE TABLET (ORAL)	0.4%	ON	Yes-Generic			
E.E.S. 200 SUSPENSION (ORAL)	0.2%	ON	Yes			
ERYTHROMYCIN BASE CAPSULE DR (ORAL)	0.0%	ON	No-Generic			
CLARITHROMYCIN ER (ORAL)	0.0%	OFF	No-Generic			
ERYPED 200 SUSPENSION (ORAL)	0.1%	ON	Yes			
ERYPED 400 SUSPENSION (ORAL)	0.0%	ON	Yes			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - All members were in favor of this motion
 - Motion passes

TETRACYCLINES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DOXYCYCLINE HYCLATE CAPSULE (ORAL)	42.7%	OFF	No-Generic			
DOXYCYCLINE HYCLATE TABLET (ORAL)	32.8%	OFF	No-Generic			
TETRACYCLINE (ORAL)	0.1%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)	0.0%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE BRAND (ORAL)	0.0%	ON	No			
ORACEA (ORAL)	0.0%	OFF	No			
VIBRAMYCIN SUSPENSION (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)	37.4%	ON	Yes-Generic			
MINOCYCLINE CAPSULES (ORAL)	23.5%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE BRAND (ORAL)	0.0%	ON	No			
DOXYCYCLINE MONOHYDRATE TABLET (ORAL)	0.0%	ON	Yes-Generic			
DOXYCYCLINE HYCLATE TABLET (20mg) (ORAL)	0.3%	ON	Yes-Generic			
SOLODYN (ORAL)	0.1%	OFF	No			
VIBRAMYCIN SYRUP (ORAL)	0.1%	OFF	No			
MINOCYCLINE TABLETS (ORAL)	0.0%	OFF	No-Generic			
DORYX (ORAL)	0.0%	OFF	No			
MINOCYCLINE ER (ORAL)	0.0%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 75 MG CAPSULE (ORAL)	0.0%	ON	No-Generic			
DEMECLOCYCLINE (ORAL)	0.2%	OFF	No-Generic			
DOXYCYCLINE HYCLATE TABLET DR (ORAL)	0.0%	OFF	No-Generic			
MORGIDOX KIT (MISCELL)	0.0%	OFF	No			

DOXYCYCLINE MONOHYDRATE 150 MG CAPSULE (ORAL)	0.0%	ON	No-Generic			
ADOXA CAPSULE (ORAL)	0.0%	OFF	No			

- Discussion:
The committee had discussion regarding the recent pricing and availability issues surrounding doxycycline hyclate and doxycycline monohydrate. Staff noted that they will continue to monitor the pricing and availability. Staff stated that only the lowest cost generic doxycycline monohydrate 50mg and 100 mg strengths are preferred. The committee noted that most prescribers do not indicate a specific doxycycline salt.
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - The vote was 8 to 1 in favor of the motion. Alicia Walker opposed.
 - Motion passes

ACNE AGENTS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BENZOYL PEROXIDE LOTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
BENZOYL PEROXIDE 10% CREAM OTC (TOPICAL)	0.0%	ON	Yes-Generic			
KLARON (TOPICAL)	0.0%	OFF	No			
DIFFERIN CREAM (TOPICAL)	2.9%	ON	Yes			
PANOXYL-8 OTC (TOPICAL)	0.0%	ON	Yes-Generic			
TAZORAC CREAM (TOPICAL)	0.3%	OFF	No			
DIFFERIN LOTION (TOPICAL)	0.3%	ON	Yes			
BENZOYL PEROXIDE 5% WASH OTC (TOPICAL)	1.8%	ON	Yes-Generic			
BENZACLIN W/PUMP (TOPICAL)	0.0%	OFF	No			
BENZOYL PEROXIDE 10% WASH OTC (TOPICAL)	0.9%	ON	Yes-Generic			
TAZORAC GEL (TOPICAL)	0.1%	OFF	No			
BENZOYL PEROXIDE GEL OTC (TOPICAL)	8.7%	ON	Yes-Generic			
AZELEX (TOPICAL)	1.4%	ON	Yes			
BENZOYL PEROXIDE GEL (TOPICAL)	1.8%	ON	Yes-Generic			
BENZOYL PEROXIDE CLEANSER (TOPICAL)	0.1%	ON	Yes-Generic			

DIFFERIN GEL (TOPICAL)	7.5%	ON	Yes			
AKNE-MYCIN (TOPICAL)	0.0%	OFF	No			
ERYTHROMYCIN GEL (TOPICAL)	2.6%	ON	Yes-Generic			
RETIN-A MICRO (TOPICAL)	7.8%	ON	Yes			
DESQUAM-X OTC (TOPICAL)	0.0%	ON	Yes			
SULFACETAMIDE / SULFUR CLEANSER (TOPICAL)	0.3%	OFF	No-Generic			
ZIANA (TOPICAL)	0.0%	OFF	No			
ATRALIN (TOPICAL)	0.0%	OFF	No			
SULFACETAMIDE / SULFUR LOTION (TOPICAL)	0.0%	OFF	No-Generic			
CERISA (TOPICAL)	0.0%	OFF	No-Generic			
ERYTHROMYCIN SOLUTION (TOPICAL)	1.4%	ON	Yes-Generic			
CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)	10.5%	ON	Yes-Generic			
BENZAOLIN (TOPICAL)	0.0%	OFF	No			
TRETINOIN GEL (TOPICAL)	5.4%	ON	Yes-Generic			
CLINDAGEL (TOPICAL)	0.0%	OFF	No			
TRETINOIN CREAM (TOPICAL)	15.6%	ON	Yes-Generic			
CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)	7.5%	ON	Yes-Generic			
SULFACETAMIDE / AVOBENZONE / SULFUR CREAM (TOPICAL)	0.0%	OFF	No-Generic			
BENZAMYCIN (TOPICAL)	0.0%	OFF	No			
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	0.1%	OFF	No-Generic			
CLINDAMYCIN PHOSPHATE GEL (TOPICAL)	21.5%	ON	Yes-Generic			
SULFACETAMIDE SUSPENSION (TOPICAL)	0.1%	OFF	No-Generic			
SULFACETAMIDE SODIUM / SULFUR CREAM (TOPICAL)	0.0%	OFF	No-Generic			
BP 10-1 (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE SODIUM / SULFUR (TOPICAL)	0.0%	OFF	No-Generic			
EPIDUO (TOPICAL)	0.2%	OFF	No			
SULFACETAMIDE / SULFUR	0.0%	OFF	No-Generic			

SUSPENSION (TOPICAL)						
ACZONE (TOPICAL)	0.3%	OFF	No			
VELTIN (TOPICAL)	0.0%	OFF	No			
CLARIFOAM EF (TOPICAL)	0.0%	OFF	No			
CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL)	0.0%	OFF	No-Generic			
ADAPALENE GEL (TOPICAL)	0.2%	OFF	No-Generic			
ADAPALENE CREAM (TOPICAL)	0.1%	OFF	No-Generic			
CLINDAMYCIN PHOSPHATE FOAM (TOPICAL)	0.1%	OFF	No-Generic			
SULFACETAMIDE / SULFUR / UREA CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
CLINDAMYCIN / BENZOYL PEROXIDE (BENZACLIN) (TOPICAL)	0.3%	OFF	No-Generic			
BENZOYL PEROXIDE MICROSPHERES CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
SSS 10-4 (TOPICAL)	0.0%	OFF	No-Generic			
AVAR CLEANSER(TOPICAL)	0.0%	OFF	No			
SULFACETAMIDE CLEANSER(TOPICAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second- Rosanne Barber
 - All members were in favor of this motion
 - Motion passes

ANTIBIOTICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NEOMYCIN / POLYMYXIN / PRAMOXINE (TOPICAL)	0.0%	ON	Yes-Generic			
DOUBLE ANTIBIOTIC OINT. OTC (TOPICAL)	0.1%	ON	Yes-Generic			
TRIPLE ANTIBIOTIC OINTMENT OTC (TOPICAL)	14.5%	ON	Yes-Generic			
BACITRACIN OTC (TOPICAL)	8.5%	ON	Yes-Generic			

GENTAMICIN OINTMENT (TOPICAL)	1.0%	ON	Yes-Generic			
BACITRACIN/POLYMYXIN OTC (TOPICAL)	1.5%	ON	Yes-Generic			
MUPIROCIN OINTMENT (TOPICAL)	73.3%	ON	Yes-Generic			
GENTAMICIN CREAM (TOPICAL)	0.8%	ON	Yes-Generic			
BACTROBAN CREAM (TOPICAL)	0.2%	OFF	No			
MUPIROCIN CREAM (TOPICAL)	0.0%	NR	No-Generic			
ALTBAX (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Alicia Walker made a motion to accept staff recommendations as presented
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

ANTIFUNGALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOLNAFTATE CREAM OTC (TOPICAL)	0.2%	ON	Yes-Generic			
TOLNAFTATE SOLUTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
MENTAX (TOPICAL)	0.0%	OFF	No			
MICONAZOLE CREAM OTC (TOPICAL)	2.3%	ON	Yes-Generic			
TINACTIN CREAM OTC (TOPICAL)	0.0%	ON	Yes			
CLOTRIMAZOLE CREAM OTC (TOPICAL)	6.6%	ON	Yes-Generic			
MICONAZOLE POWDER OTC (TOPICAL)	0.1%	ON	Yes-Generic			
CLOTRIMAZOLE SOLUTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
CLOTRIMAZOLE CREAM RX (TOPICAL)	13.3%	ON	Yes-Generic			
LOTRIMIN AF CREAM OTC (TOPICAL)	0.0%	ON	Yes			
MICONAZOLE OINT OTC (TOPICAL)	0.0%	ON	Yes-Generic			
CICLOPIROX SOLUTION (TOPICAL)	0.2%	OFF	No-Generic			

EXELDERM SOLUTION (TOPICAL)	0.0%	OFF	No			
CICLOPIROX CREAM (TOPICAL)	0.0%	OFF	No-Generic			
EXELDERM CREAM (TOPICAL)	0.0%	OFF	No			
ECONAZOLE (TOPICAL)	0.2%	OFF	No-Generic			
CICLODAN CREAM (TOPICAL)	0.0%	OFF	No			
CLOTRIMAZOLE SOLUTION RX (TOPICAL)	0.6%	ON	Yes-Generic			
ERTACZO (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE SHAMPOO (TOPICAL)	11.0%	ON	Yes-Generic			
FUNGOID OTC (TOPICAL)	0.0%	ON	Yes			
KETOCONAZOLE CREAM (TOPICAL)	9.9%	ON	Yes-Generic			
NYSTATIN CREAM (TOPICAL)	19.5%	ON	Yes-Generic			
NYSTATIN OINT (TOPICAL)	9.7%	ON	Yes-Generic			
CICLOPIROX SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
NYSTATIN POWDER (TOPICAL)	9.2%	ON	Yes-Generic			
OXISTAT CREAM (TOPICAL)	0.0%	OFF	No			
CICLOPIROX GEL (TOPICAL)	0.0%	OFF	No-Generic			
CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)	10.4%	ON	Yes-Generic			
OXISTAT LOTION (TOPICAL)	0.0%	OFF	No			
VUSION (TOPICAL)	0.0%	OFF	No			
CICLOPIROX SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
CLOTRIMAZOLE-BETAMETHASONE LOTION (TOPICAL)	0.6%	ON	Yes-Generic			
BENSAL HP (TOPICAL)	0.0%	OFF	No			
NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)	4.8%	ON	Yes-Generic			
NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)	1.3%	ON	Yes-Generic			
NAFTIN GEL (TOPICAL)	0.0%	OFF	No			

NAFTIN CREAM (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE FOAM (TOPICAL)	0.0%	OFF	No-Generic			
EXTINA (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Alicia Walker made a motion to accept staff recommendations as presented
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

ANTIPARASITICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PERMETHRIN OTC (TOPICAL)	24.1%	ON	Yes-Generic			
EURAX CREAM (TOPICAL)	0.2%	ON	Yes			
EURAX LOTION (TOPICAL)	0.0%	OFF	No			
ULESFIA (TOPICAL)	0.2%	OFF	Yes			
NATROBA (TOPICAL)	0.0%	OFF	No			
PERMETHRIN (TOPICAL)	68.0%	ON	Yes-Generic			
SKLICE (TOPICAL)	0.1%	NR	No			
LINDANE SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
LINDANE LOTION (TOPICAL)	0.0%	OFF	No-Generic			
SPINOSAD (TOPICAL)	0.0%	NR	No-Generic			
MALATHION BRAND (TOPICAL)	7.3%	ON	Yes-Generic			
OVIDE (TOPICAL)	0.1%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion
 - Motion passes

ANTIVIRALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DENA VIR (TOPICAL)	24.6%	ON	Yes			
ZOVIRAX CREAM (TOPICAL)	0.1%	OFF	No			
ZOVIRAX OINTMENT (TOPICAL)	75.2%	ON	Yes			

XERESE (TOPICAL)	0.0%	OFF	No			
------------------	------	-----	----	--	--	--

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

ANALGESICS, MISCELLANEOUS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ASPIRIN TABLET OTC (ORAL)	68.4%	ON	Yes-Generic			
ASPIRIN TAB CHEW OTC (ORAL)	18.3%	ON	Yes-Generic			
IBUPROFEN TABLET OTC (ORAL)	4.3%	ON	Yes-Generic			
NAPROXEN SODIUM OTC (ORAL)	0.8%	ON	Yes-Generic			
IBUPROFEN SUSPENSION OTC (ORAL)	2.6%	ON	Yes-Generic			
IBUPROFEN TAB CHEW OTC (ORAL)	0.1%	ON	Yes-Generic			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.1%	ON	Yes-Generic			
BUTALBITAL / APAP / CAFFEINE (ORAL)	4.4%	OFF	No-Generic			
BUTALBITAL / CAFFEINE / APAP W/CODEINE (ORAL)	0.3%	OFF	No-Generic			
BUTALBITAL / ASA / CAFFEINE (ORAL)	0.6%	OFF	No-Generic			
BUTALBITAL COMPOUND W/CODEINE (ORAL)	0.2%	OFF	No-Generic			

- Discussion:
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion.
 - Motion passes

ANALGESICS, NARCOTICS LONG						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METHADONE SOUTION (ORAL)	0.2%	ON	Yes-Generic			

METHADONE CONC (ORAL)	6.8%	ON	Yes-Generic			
METHADONE TABLET (ORAL)	17.1%	ON	Yes-Generic			
METHADONE SOL TABLET (ORAL)	0.0%	ON	Yes-Generic			
MORPHINE ER TABLET (ORAL)	35.2%	ON	Yes-Generic			
KADIAN (ORAL)	0.4%	OFF	No			
FENTANYL (TRANSDERM)	21.8%	ON	Yes-Generic			
TRAMADOL ER (ORAL)	0.2%	OFF	No-Generic			
CONZIP (ORAL)	0.0%	OFF	No			
BUTRANS (TRANSDERM)	2.7%	ON	Yes			
OPANA ER (ORAL)	0.8%	OFF	No			
RYZOLT (ORAL)	0.0%	OFF	No			
NUCYNTA ER (ORAL)	0.3%	OFF	No			
TRAMADOL ER (GENERIC RYZOLT ER) (ORAL)	0.0%	OFF	No-Generic			
OXYMORPHONE ER (ORAL)	0.1%	OFF	No-Generic			
AVINZA (ORAL)	0.1%	OFF	No			
MORPHINE ER CAPSULE (KADIAN) (ORAL)	0.4%	OFF	No-Generic			
OXYCONTIN (ORAL)	13.7%	OFF	No			
EXALGO (ORAL)	0.2%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion
 - Motion passes

ANALGESICS, NARCOTICS SHORT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MEPERIDINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
APAP / CODEINE ELIXIR (ORAL)	0.8%	ON	Yes-Generic			
TRAMADOL (ORAL)	15.4%	ON	Yes-Generic			
MORPHINE SOLUTION (ORAL)	0.0%	ON	Yes-Generic			
OXYCODONE / APAP CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
APAP / CODEINE TABLET (ORAL)	6.1%	ON	Yes-Generic			
HYDROCODONE / APAP	0.7%	ON	Yes-Generic			

SOLUTION (ORAL)						
HYDROCODONE / APAP TABLET(5) (ORAL)	32.8%	ON	Yes-Generic			
MORPHINE IR TABLET (ORAL)	0.7%	ON	Yes-Generic			
MEPERIDINE TABLET (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE / APAP TABLET (ORAL)	16.6%	ON	Yes-Generic			
HYDROCODONE / IBUPROFEN (ORAL)	0.4%	ON	Yes-Generic			
HYDROCODONE / APAP CAPSULE (ORAL)	0.0%	ON	Yes-Generic			
DILAUDID LIQUID (ORAL)	0.0%	OFF	No			
HYDROCODONE / APAP TABLET (ORAL)	12.2%	ON	No-Generic			
CODEINE (ORAL)	0.1%	ON	Yes-Generic			
HYDROMORPHONE TABLET (ORAL)	0.7%	ON	Yes-Generic			
BUTALBITAL / CAFFEINE / APAP W/CODEINE (ORAL)	0.0%	OFF	No-Generic			
MORPHINE CONC SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
HYDROMORPHONE SUPPOSITORIES (RECTAL)	0.0%	OFF	No-Generic			
ZOLVIT (ORAL)	0.0%	OFF	No			
TRAMADOL / APAP (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE TABLET (ORAL)	12.7%	ON	Yes-Generic			
OXYCODONE / IBUPROFEN (ORAL)	0.0%	OFF	No-Generic			
MORPHINE CONC SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
HYDROMORPHONE SUPPOSITORIES (RECTAL)	0.0%	OFF	No-Generic			
ZOLVIT (ORAL)	0.0%	OFF	No			
TRAMADOL / APAP (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE TABLET (ORAL)	12.7%	ON	Yes-Generic			
OXYCODONE / IBUPROFEN (ORAL)	0.0%	OFF	No-Generic			
ZYDONE (ORAL)	0.0%	ON	No			
CODEINE SOLUTION (ORAL)	0.0%	ON	Yes-Generic			
REPREXAIN (ORAL)	0.0%	OFF	No			
IBUDONE (ORAL)	0.0%	OFF	No			
OXYCODONE / ASA BRAND (ORAL)	0.0%	OFF	No			
OXYCODONE / ASA (ORAL)	0.0%	OFF	No-Generic			
HYDROMORPHONE LIQUID (ORAL)	0.0%	NR	No-Generic			

OXYCODONE CAPSULE (ORAL)	0.1%	ON	No-Generic			
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	0.0%	OFF	No-Generic			
ZAMICET (ORAL)	0.0%	OFF	No			
HYCET (ORAL)	0.0%	OFF	No			
RYBIX ODT (ORAL)	0.0%	OFF	No			
PENTAZOCINE / NALOXONE (ORAL)	0.0%	OFF	No-Generic			
PRIMLEV (ORAL)	0.0%	OFF	No			
NUCYNTA (ORAL)	0.1%	OFF	No			
CAPITAL W-CODEINE (ORAL)	0.0%	ON	Yes			
CARISOPRODOL COMPOUND-CODEINE (ORAL)	0.0%	OFF	No-Generic			
LEVORPHANOL (ORAL)	0.0%	OFF	No-Generic			
OXECTA (ORAL)	0.0%	OFF	No			
OXYMORPHONE (ORAL)	0.0%	OFF	No-Generic			
XODOL (ORAL)	0.0%	OFF	No			
MAGNACET (ORAL)	0.0%	OFF	No			
ONSOLIS (BUCCAL)	0.0%	OFF	No			
ABSTRAL (SUBLINGUAL)	0.0%	OFF	No			
OXYCODONE CONC (ORAL)	0.0%	OFF	No-Generic			
FENTORA (BUCCAL)	0.0%	OFF	No			
SUBSYS (SUBLINGUAL)	0.0%	NR	No			
FENTANYL (BUCCAL)	0.0%	OFF	No-Generic			

- Discussion:
Lynn commented that only hydrocodone products with 325mg or 500mg of acetaminophen will be the only preferred hydrocodone/acetaminophen combination products.
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

OPIATE DEPENDENCY						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BUPRENORPHINE HCL (SUBLINGUAL)	9.0%	ON	Yes-Generic			
SUBOXONE FILM (SUBLINGUAL)	89.6%	ON	Yes			
BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL)	0.0%	NR	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Rosanne Barber
 - All members were in favor of this motion
 - Motion passes

ANTIMIGRAINE AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IMITREX (NASAL)	2.4%	ON	Yes			
SUMATRIPTAN (ORAL)	68.8%	ON	Yes-Generic			
RELPAK (ORAL)	7.0%	ON	Yes			
FROVA (ORAL)	0.3%	OFF	No			
RIZATRIPTAN TABLET (ORAL)	0.0%	NR	Yes-Generic			
MAXALT MLT (ORAL)	1.6%	OFF	No			
ZOMIG (ORAL)	0.4%	OFF	No			
AXERT (ORAL)	0.2%	OFF	No			
NARATRIPTAN (ORAL)	10.4%	ON	Yes-Generic			
ZOMIG ZMT (ORAL)	0.3%	OFF	No			
ZOMIG (NASAL)	0.1%	OFF	No			
TREXIMET (ORAL)	0.3%	OFF	No			
CAMBIA (ORAL)	0.0%	OFF	No			
SUMATRIPTAN VIAL (SUBCUTANE.)	0.0%	OFF	No-Generic			
MAXALT TABLET (ORAL)	2.6%	OFF	No			
IMITREX KIT (SUBCUTANE.)	4.1%	ON	Yes			
IMITREX VIAL (SUBCUTANE.)	0.1%	ON	Yes			
SUMATRIPTAN (NASAL)	0.3%	OFF	No-Generic			
RIZATRIPTAN ODT (ORAL)	0.0%	NR	No-Generic			
SUMATRIPTAN KIT (SUBCUTANE.)	0.5%	OFF	No-Generic			
SUMATRIPTAN KIT (SUN) (SUBCUTANE.)	0.5%	OFF	No-Generic			
SUMAVEL DOSEPRO (SUBCUTANE.)	0.00%	OFF	No			
ALSUMA (SUBCUTANEOUS)	0.0%	NR	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

SKELETAL MUSCLE RELAXANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CYCLOBENZAPRINE (ORAL)	61.5%	ON	Yes-Generic			
CHLORZOXAZONE (ORAL)	0.5%	ON	Yes-Generic			
BACLOFEN (ORAL)	14.0%	ON	Yes-Generic			
TIZANIDINE TABLETS (ORAL)	15.2%	ON	Yes-Generic			
METHOCARBAMOL (ORAL)	6.0%	ON	Yes-Generic			
CARISOPRODOL (ORAL)	1.7%	OFF	No-Generic			
ORPHENADRINE COMPOUND (ORAL)	0.0%	OFF	No-Generic			
ORPHENADRINE (ORAL)	0.1%	OFF	No-Generic			
ZANAFLEX CAPSULE (ORAL)	0.0%	OFF	No			
SOMA 250 MG (ORAL)	0.0%	OFF	No			
DANTROLENE SODIUM (ORAL)	0.3%	ON	Yes-Generic			
CARISOPRODOL COMPOUND (ORAL)	0.0%	OFF	No-Generic			
DANTRIUM (ORAL)	0.0%	OFF	No-Generic			
FEXMID (ORAL)	0.0%	OFF	No			
CARISOPRODOL 250 MG (ORAL)	0.1%	OFF	No-Generic			
LORZONE (ORAL)	0.0%	OFF	No			
METAXALONE (ORAL)	0.5%	OFF	No-Generic			
AMRIX (ORAL)	0.0%	OFF	No			
TIZANIDINE CAPSULES (ORAL)	0.0%	OFF	No-Generic			
CYCLOBENZAPRINE ER (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

BLADDER RELAXANT PREPARATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SANCTURA XR (ORAL)	0.4%	OFF	No			
OXYBUTYNIN TABLET (ORAL)	36.8%	ON	Yes-Generic			

OXYBUTYNIN SYRUP (ORAL)	2.4%	ON	Yes-Generic			
OXYTROL (TRANSDERM.)	0.2%	OFF	No			
SANCTURA (ORAL)	0.0%	OFF	No			
ENABLEX (ORAL)	1.7%	OFF	No			
TOVIAZ (ORAL)	7.8%	ON	Yes			
VESICARE (ORAL)	42.8%	ON	Yes			
GELNIQUE (TRANSDERM.)	0.2%	OFF	No			
OXYBUTYNIN ER (ORAL)	4.4%	OFF	No-Generic			
DETROL LA (ORAL)	2.7%	OFF	No			
TOLTERODINE (ORAL)	0.2%	NR	No-Generic			
GELNIQUE GEL MD PMP (TRANSDERMAL)	0.0%	NR	No			
TROSPIUM (ORAL)	0.2%	OFF	No-Generic			
DETROL (ORAL)	0.1%	OFF	No			
TROSPIUM ER (ORAL)	0.2%	NR	No-Generic			
MYRBETRIQ (ORAL)	0.0%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second- Pat Towers
 - All members were in favor of this motion
 - Motion passes

BONE RESORPTION SUPPRESSION AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALENDRONATE TABLETS (ORAL)	87.7%	ON	Yes-Generic			
FORTICAL (NASAL)	4.1%	OFF	Yes			
ACTONEL (ORAL)	1.7%	OFF	No			
BINOSTO (ORAL)	0.0%	NR	No			
MIACALCIN (NASAL)	4.5%	ON	No			
ETIDRONATE DISODIUM (ORAL)	0.0%	OFF	No-Generic			
BONIVA (ORAL)	0.3%	OFF	No			
FOSAMAX PLUS D (ORAL)	0.2%	OFF	No			
EVISTA (ORAL)	3.6%	OFF	No			

ATELVIA (ORAL)	0.1%	OFF	No			
CALCITONIN SALMON (NASAL)	0.4%	OFF	No-Generic			
IBANDRONATE TABLETS (ORAL)	1.3%	NR	No-Generic			

- Discussion:
Staff stated that members currently taking Miacalcin will not be grandfathered.
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion
 - Motion passes

ERYTHROPOIESIS STIMULATING PROTEINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPOGEN (INJECTION)	0.0%	OFF	No			
PROCRIT (INJECTION)	82.6%	ON	Yes			
ARANESP VIAL (INJECTION)	5.4%	ON	Yes			
ARANESP DISP SYRIN (INJECTION)	12.0%	ON	Yes			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion
 - Motion passes

GROWTH HORMONE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OMNITROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
SAIZEN VIAL (INJECTION)	0.0%	ON	No			
SAIZEN CARTRIDGE (INJECTION)	0.0%	ON	No			
NUTROPIN AQ CARTRIDGE (INJECTION)	12.3%	ON	Yes			
NORDITROPIN PEN (INJECTION)	76.5%	ON	Yes			
NUTROPIN VIAL (INJECTION)	0.0%	ON	Yes			

HUMATROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
HUMATROPE VIAL (INJECTION)	0.0%	OFF	No			
TEV-TROPIN VIAL (INJECTION)	0.0%	OFF	No			
GENOTROPIN CARTRIDGE (INJECTION)	5.8%	OFF	No			
GENOTROPIN DISP SYRIN (INJECTION)	5.3%	OFF	No			
OMNITROPE VIAL (INJECTION)	0.0%	OFF	No			
SEROSTIM VIAL (INJECTION)	0.0%	OFF	No			
ZORBITIVE VIAL (INJECTION)	0.0%	OFF	No			

- Discussion:
Rachel indicated that Clinical PA is required on all Growth Hormone products.
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second- Alicia Walker
 - All members were in favor of this motion
 - Motion passes

ANDROGENIC AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TESTIM (TRANSDERM.)	5.8%	ON	Yes			
ANDROGEL GEL PACKET (TRANSDERM.)	33.5%	ON	Yes			
ANDROGEL GEL PUMP (TRANSDERM)	45.7%	ON	Yes			
ANDRODERM (TRANSDERM)	13.6%	ON	No			
FORTESTA (TRANSDERM)	0.0%	OFF	No			
AXIRON (TRANSDERM)	1.4%	OFF	No			

- Discussion: None
- Alicia Walker made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion
 - Motion passes

BPH TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TAMSULOSIN (ORAL)	55.0%	ON	Yes-Generic			
DOXAZOSIN (ORAL)	14.9%	ON	Yes-Generic			
TERAZOSIN (ORAL)	7.4%	ON	Yes-Generic			
FINASTERIDE (ORAL)	21.2%	ON	Yes-Generic			
ALFUZOSIN (ORAL)	0.3%	OFF	Yes-Generic			
CARDURA XL (ORAL)	0.0%	OFF	No			
RAPAFLO (ORAL)	0.2%	OFF	No			
AVODART (ORAL)	0.9%	OFF	No			
JALYN (ORAL)	0.2%	OFF	No			

- Discussion:
 - Alicia Walker asked why we should add the generic alfuzosin. Steve Maike commented that offering this generic may prevent other brand product use.
- William Raduege made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion
 - Motion passes

PHOSPHATE BINDERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PHOSLYRA (ORAL)	0.5%	OFF	No			
CALCIUM ACETATE TABLET (ORAL)	0.0%	OFF	Yes-Generic			
CALCIUM ACETATE CAPSULE (ORAL)	41.2%	ON	Yes-Generic			
ELIPHOS (ORAL)	0.0%	ON	No			
RENAGEL (ORAL)	45.2%	ON	Yes			
FOSRENOL (ORAL)	6.4%	ON	Yes			
RENVELA TABLET (ORAL)	5.5%	OFF	No			
RENVELA POWDER PACK (ORAL)	1.2%	OFF	No			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- Al Liegel
 - All members were in favor of this motion
 - Motion passes

HEPATITIS B AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPIVIR HBV TABLET (ORAL)	20.7%	ON	Yes			
BARACLUDE SOLUTION (ORAL)	4.3%	ON	Yes			
HEPSERA (ORAL)	3.4%	ON	Yes			
BARACLUDE TABLET (ORAL)	71.6%	ON	Yes			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

HEPATITIS C AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PEG-INTRON (SUBCUTANE.)	0.0%	ON	Yes			
RIBAVIRIN TABLET (ORAL)	22.6%	ON	Yes-Generic			
RIBAVIRIN CAPSULE (ORAL)	16.6%	ON	Yes-Generic			
PEG-INTRON REDIPEN (SUBCUTANE.)	8.8%	ON	Yes			
RIBASPHERE 400 MG (ORAL)	0.0%	OFF	No			
REBETOL SOLUTION (ORAL)	0.0%	ON	Yes			
PEGASYS VIAL	0.7%	ON	Yes			

(SUBCUTANE.)						
PEGASYS SYRINGE (SUB-Q)	22.2%	ON	Yes			
PEGASYS PROCLICK (SUB-Q)	12.9%	ON	Yes			
RIBASPHERE 600 MG (ORAL)	0.0%	OFF	No			
RIBAPAK (ORAL)	0.0%	OFF	No			
VICTRELIS (ORAL)	6.9%	ON	Yes			
INCIVEK (ORAL)	9.2%	ON	Yes			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- William Radeuge
 - All members were in favor of this motion
 - Motion passes

HIV/AIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VIRAMUNE SUSPENSION (ORAL)	0.1%	ON	Yes			
VIRAMUNE TABLET (ORAL)	0.8%	ON	Yes			
ZIDOVUDINE TABLET (ORAL)	0.1%	ON	Yes-Generic			
NEVIRAPINE TABLET (ORAL)	0.0%	NR	Yes-Generic			
NORVIR CAPSULE (ORAL)	2.0%	ON	Yes			
NORVIR TABLET (ORAL)	16.1%	ON	Yes			
ZIDOVUDINE SYRUP (ORAL)	0.5%	ON	Yes-Generic			
NORVIR SOLUTION (ORAL)	0.0%	ON	Yes			
STAVUDINE CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
SUSTIVA CAPSULE (ORAL)	0.2%	ON	Yes			
EPIVIR SOLUTION (ORAL)	0.2%	ON	Yes			
VIRAMUNE XR (ORAL)	0.7%	ON	Yes			
EMTRIVA SOLUTION (ORAL)	0.0%	ON	Yes			
ZIDOVUDINE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			

ZIAGEN SOLUTION (ORAL)	0.4%	ON	Yes			
DIDANOSINE (ORAL)	0.0%	OFF	No-Generic			
EPIVIR TABLET (ORAL)	0.9%	ON	Yes			
NEVIRAPINE ORAL SUSP (ORAL)	0.0%	NR	Yes-Generic			
VIDEX (ORAL)	0.1%	ON	Yes			
RESCRIPTOR (ORAL)	0.0%	OFF	No			
EMTRIVA CAPSULE (ORAL)	0.2%	ON	Yes			
LEXIVA SUSPENSION (ORAL)	0.0%	ON	Yes			
LAMIVUDINE TABLET (ORAL)	0.0%	OFF	No-Generic			
APTIVUS SOLUTION (ORAL)	0.0%	OFF	No			
ZIAGEN TABLET (ORAL)	1.5%	ON	Yes			
STAVUDINE SOLUTION (ORAL)	0.0%	ON	Yes-Generic			
CRIXIVAN (ORAL)	0.0%	ON	Yes			
ZERIT SOLUTION (ORAL)	0.0%	ON	Yes			
VIREAD (ORAL)	4.5%	ON	Yes			
ISENTRESS TAB CHEW (ORAL)	0.0%	NR	Yes			
SUSTIVA TABLET (ORAL)	0.7%	ON	Yes			
ABACAVIR (ORAL)	0.1%	OFF	No-Generic			
INVIRASE CAPSULE (ORAL)	0.0%	ON	Yes			
INVIRASE TABLET (ORAL)	0.1%	ON	Yes			
COMBIVIR (ORAL)	1.4%	ON	Yes			
KALETRA SOLUTION (ORAL)	0.3%	ON	Yes			
EDURANT (ORAL)	0.1%	ON	Yes			
EPZICOM (ORAL)	2.5%	ON	Yes			
KALETRA TABLET (ORAL)	2.6%	ON	Yes			
VIRACEPT (ORAL)	0.2%	OFF	No			
TRUVADA (ORAL)	20.4%	ON	Yes			
LEXIVA TABLET (ORAL)	0.8%	ON	Yes			
LAMIVUDINE-ZIDOVUDINE (ORAL)	0.1%	OFF	No-Generic			
INTELENCE (ORAL)	1.2%	OFF	No			

REYATAZ (ORAL)	8.5%	ON	Yes			
ISENTRESS (ORAL)	6.3%	ON	Yes			
PREZISTA (ORAL)	9.9%	ON	Yes			
SELZENTRY (ORAL)	0.6%	OFF	No			
APTIVUS CAPSULE (ORAL)	0.0%	OFF	No			
TRIZIVIR (ORAL)	1.0%	ON	Yes			
ATRIPLA (ORAL)	10.7%	ON	Yes			
COMPLERA (ORAL)	3.0%	ON	Yes			
FUZEON (SUB-Q)	0.0%	OFF	No			
STRIBILD (ORAL)	0.8%	NR	No			

- Discussion:
Rachel Currans-Henry and Rick Pope explained to the committee that the WHO guidelines indicate HIV treatment should be started early. New guidelines are expected late summer 2013. Current guidelines do not indicate Stribild as a preferred treatment. Staff consulted with DHS Public Health regarding Stribild's status. Public Health staff felt it would be a prudent approach to continue Stribild's non-preferred status until further guidelines are available.
- Al Liegel made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion
 - Motion passes

MULTIPLE SCLEROSIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
COPAXONE (SUBCUTANE.)	44.7%	ON	Yes			
AVONEX PEN (INTRAMUSC)	6.0%	NR	Yes			
AVONEX (INTRAMUSC.)	12.9%	ON	Yes			
REBIF (SUBCUTANE.)	19.1%	ON	Yes			
BETASERON (SUBCUTANE.)	10.2%	ON	Yes			

EXTAVIA KIT (SUBCUTANE.)	0.0%	NR	No			
AMPYRA (ORAL)	3.4%	OFF	No			
EXTAVIA VIAL (SUBCUTANE.)	0.0%	NR	No			
AUBAGIO (ORAL)	0.1%	NR	No			
GILENYA (ORAL)	3.5%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second- Ward Brown
 - All members were in favor of this motion
 - Motion passes

IRRITABLE BOWEL SYNDROME- NEW CLASS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMITIZA (ORAL)	99.9%	NR	Yes			
LINZESS (ORAL)	0.1%	NR	Yes			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second- William Raduege
 - All members were in favor of this motion
 - Motion passes

H2 ANTAGONISTS- NEW CLASS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FAMOTIDINE TABLET (ORAL)	20.1%	NR	Yes-Generic			
RANITIDINE TABLET (ORAL)	55.0%	NR	Yes-Generic			
AXID SOLUTION (ORAL)	0.0%	NR	No			
RANITIDINE SYRUP (ORAL)	19.1%	NR	Yes-Generic			
CIMETIDINE TABLET (ORAL)	1.4%	NR	Yes-Generic			
CIMETIDINE SOLUTION(ORAL)	0.1%	NR	Yes-Generic			

NIZATIDINE CAPSULE (ORAL)	0.4%	NR	No-Generic			
RANITIDINE CAPSULE (ORAL)	3.3%	NR	No-Generic			
NIZATIDINE SOLUTION (ORAL)	0.2%	NR	No-Generic			
FAMOTIDINE SUSPENSION (ORAL)	0.6%	NR	No-Generic			

- Discussion:
Catherine Decker asked if these products covered in this class are OTC as well as RX. Lynn commented that they are RX formulations only and OTCs are not covered.
- Alicia Walker made a motion to accept staff recommendations as presented.
 - Second- Steve Maike
 - All members were in favor of this motion
 - Motion passes